China SXT Pharmaceuticals, Inc. (SXTC)
NASDAQ: SXTC · Real-Time Price · USD
2.400
-0.035 (-1.44%)
At close: Sep 18, 2026, 4:00 PM EDT
2.350
-0.050 (-2.08%)
After-hours: Sep 18, 2026, 7:47 PM EDT
China SXT Pharmaceuticals Income Statement
Financials in millions USD. Fiscal year is April - March.
Millions USD. Fiscal year is Apr - Mar.
Fiscal Quarter | H2 2026 | H1 2026 | H2 2025 | H1 2025 | H2 2024 | H1 2024 | H2 2023 | H1 2023 | H2 2022 | H1 2022 |
|---|---|---|---|---|---|---|---|---|---|---|
Period Ending | Mar '26 Mar 31, 2026 | Sep '25 Sep 30, 2025 | Mar '25 Mar 31, 2025 | Sep '24 Sep 30, 2024 | Mar '24 Mar 31, 2024 | Sep '23 Sep 30, 2023 | Mar '23 Mar 31, 2023 | Sep '22 Sep 30, 2022 | Mar '22 Mar 31, 2022 | Sep '21 Sep 30, 2021 |
| 0.51 | 0.63 | 0.91 | 0.83 | 0.99 | 0.94 | 0.76 | 1.21 | 1.57 | 1.03 | |
Revenue Growth (YoY) | -43.88% | -24.46% | -7.84% | -11.72% | 29.54% | -22.24% | -51.52% | 17.57% | 71.70% | -73.38% |
Cost of Revenue | 0.36 | 0.52 | 0.68 | 0.69 | 0.72 | 0.65 | 0.43 | 1.12 | 0.65 | 0.7 |
Gross Profit | 0.15 | 0.1 | 0.23 | 0.13 | 0.27 | 0.29 | 0.34 | 0.09 | 0.93 | 0.32 |
Selling, General & Admin | 0.93 | 6.44 | 2.27 | 0.77 | -6.99 | 9.64 | 4.44 | 1.24 | 3.23 | 3.22 |
Operating Expenses | 0.93 | 6.44 | 2.27 | 0.77 | -6.99 | 9.64 | 4.44 | 1.24 | 3.23 | 3.22 |
Operating Income | -0.78 | -6.34 | -2.04 | -0.64 | 7.26 | -9.35 | -4.11 | -1.15 | -2.3 | -2.89 |
Interest Expense | -0.03 | -0.03 | -0.47 | -0.18 | -0.22 | -0.34 | -0.09 | -0.38 | -0.04 | - |
Interest & Investment Income | - | - | 0 | - | 0.01 | - | - | - | 0 | 0 |
Other Non Operating Income (Expenses) | 0.98 | 0 | 0.01 | 0.02 | -0.03 | -0.01 | 0.11 | 0.04 | -0.31 | 0.13 |
EBT Excluding Unusual Items | 0.16 | -6.37 | -2.5 | -0.8 | 7.02 | -9.7 | -4.09 | -1.49 | -2.64 | -2.77 |
Asset Writedown | - | - | - | - | -0.42 | - | -0.35 | - | - | - |
Pretax Income | 0.16 | -6.37 | -2.5 | -0.8 | 6.6 | -9.7 | -4.44 | -1.49 | -2.64 | -2.77 |
Income Tax Expense | - | - | - | - | - | - | - | - | 0 | 0.33 |
Net Income | 0.16 | -6.37 | -2.5 | -0.8 | 6.6 | -9.7 | -4.44 | -1.49 | -2.64 | -3.09 |
Net Income to Common | 0.16 | -6.37 | -2.5 | -0.8 | 6.6 | -9.7 | -4.44 | -1.49 | -2.64 | -3.09 |
Net Income Growth (YoY) | - | - | - | - | - | - | - | - | - | - |
Shares Outstanding (Basic) | - | - | - | - | - | - | - | - | 2 | 17 |
Shares Outstanding (Diluted) | - | - | - | - | - | - | - | - | 2 | 17 |
Shares Change (YoY) | - | - | - | - | - | - | - | - | -86.91% | -72.81% |
EPS (Basic) | - | - | - | - | - | - | - | - | -1.30 | -0.18 |
EPS (Diluted) | - | - | - | - | - | - | - | - | -1.30 | -0.18 |
EPS Growth (YoY) | - | - | - | - | - | - | - | - | - | - |
Additional Metrics
Fiscal Quarter | H2 2026 | H1 2026 | H2 2025 | H1 2025 | H2 2024 | H1 2024 | H2 2023 | H1 2023 | H2 2022 | H1 2022 |
|---|---|---|---|---|---|---|---|---|---|---|
Period Ending | Mar '26 Mar 31, 2026 | Sep '25 Sep 30, 2025 | Mar '25 Mar 31, 2025 | Sep '24 Sep 30, 2024 | Mar '24 Mar 31, 2024 | Sep '23 Sep 30, 2023 | Mar '23 Mar 31, 2023 | Sep '22 Sep 30, 2022 | Mar '22 Mar 31, 2022 | Sep '21 Sep 30, 2021 |
Free Cash Flow | -2.26 | -1.75 | -0.99 | -1.36 | -1.36 | -0.58 | 0.42 | -0.57 | 0.54 | -0.33 |
Free Cash Flow Per Share | - | - | - | - | - | - | - | - | 0.27 | -0.02 |
Operating Margin | -153.28% | -1011.69% | -224.07% | -76.95% | 733.81% | -995.02% | -538.08% | -95.21% | -145.95% | -281.37% |
Profit Margin | 32.01% | -1016.46% | -274.42% | -96.75% | 667.16% | -1031.96% | -581.64% | -123.70% | -167.93% | -300.86% |
Free Cash Flow Margin | -442.81% | -279.71% | -108.64% | -163.62% | -137.07% | -61.68% | 54.73% | -47.11% | 34.25% | -32.45% |
EBITDA | -0.74 | -6.31 | -2.03 | -0.57 | 7.36 | -9.25 | -3.97 | -1.04 | -2.16 | -2.71 |
D&A For EBITDA | 0.04 | 0.03 | 0.01 | 0.07 | 0.1 | 0.1 | 0.14 | 0.11 | 0.13 | 0.19 |
EBIT | -0.78 | -6.34 | -2.04 | -0.64 | 7.26 | -9.35 | -4.11 | -1.15 | -2.3 | -2.89 |
Revenue as Reported | 0.51 | 0.63 | 0.91 | 0.83 | 0.99 | 0.94 | 0.76 | 1.21 | 1.57 | 1.03 |